Corrigendum to “Construction of a novel immune response prediction signature to predict the efficacy of immune checkpoint inhibitors in clear cell renal cell carcinoma patients” Heliyon 9(6), (May 25, 2023)()

Detalles Bibliográficos
Autores principales: Yao, Jiannan, Liang, Ziwei, Duan, Ling, Ge, Yang, Liu, Jian, An, Guangyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404658/
https://www.ncbi.nlm.nih.gov/pubmed/37554844
http://dx.doi.org/10.1016/j.heliyon.2023.e18515
_version_ 1785085344649052160
author Yao, Jiannan
Liang, Ziwei
Duan, Ling
Ge, Yang
Liu, Jian
An, Guangyu
author_facet Yao, Jiannan
Liang, Ziwei
Duan, Ling
Ge, Yang
Liu, Jian
An, Guangyu
author_sort Yao, Jiannan
collection PubMed
description
format Online
Article
Text
id pubmed-10404658
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-104046582023-08-08 Corrigendum to “Construction of a novel immune response prediction signature to predict the efficacy of immune checkpoint inhibitors in clear cell renal cell carcinoma patients” Heliyon 9(6), (May 25, 2023)() Yao, Jiannan Liang, Ziwei Duan, Ling Ge, Yang Liu, Jian An, Guangyu Heliyon Research Article Elsevier 2023-07-23 /pmc/articles/PMC10404658/ /pubmed/37554844 http://dx.doi.org/10.1016/j.heliyon.2023.e18515 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Yao, Jiannan
Liang, Ziwei
Duan, Ling
Ge, Yang
Liu, Jian
An, Guangyu
Corrigendum to “Construction of a novel immune response prediction signature to predict the efficacy of immune checkpoint inhibitors in clear cell renal cell carcinoma patients” Heliyon 9(6), (May 25, 2023)()
title Corrigendum to “Construction of a novel immune response prediction signature to predict the efficacy of immune checkpoint inhibitors in clear cell renal cell carcinoma patients” Heliyon 9(6), (May 25, 2023)()
title_full Corrigendum to “Construction of a novel immune response prediction signature to predict the efficacy of immune checkpoint inhibitors in clear cell renal cell carcinoma patients” Heliyon 9(6), (May 25, 2023)()
title_fullStr Corrigendum to “Construction of a novel immune response prediction signature to predict the efficacy of immune checkpoint inhibitors in clear cell renal cell carcinoma patients” Heliyon 9(6), (May 25, 2023)()
title_full_unstemmed Corrigendum to “Construction of a novel immune response prediction signature to predict the efficacy of immune checkpoint inhibitors in clear cell renal cell carcinoma patients” Heliyon 9(6), (May 25, 2023)()
title_short Corrigendum to “Construction of a novel immune response prediction signature to predict the efficacy of immune checkpoint inhibitors in clear cell renal cell carcinoma patients” Heliyon 9(6), (May 25, 2023)()
title_sort corrigendum to “construction of a novel immune response prediction signature to predict the efficacy of immune checkpoint inhibitors in clear cell renal cell carcinoma patients” heliyon 9(6), (may 25, 2023)()
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404658/
https://www.ncbi.nlm.nih.gov/pubmed/37554844
http://dx.doi.org/10.1016/j.heliyon.2023.e18515
work_keys_str_mv AT yaojiannan corrigendumtoconstructionofanovelimmuneresponsepredictionsignaturetopredicttheefficacyofimmunecheckpointinhibitorsinclearcellrenalcellcarcinomapatientsheliyon96may252023
AT liangziwei corrigendumtoconstructionofanovelimmuneresponsepredictionsignaturetopredicttheefficacyofimmunecheckpointinhibitorsinclearcellrenalcellcarcinomapatientsheliyon96may252023
AT duanling corrigendumtoconstructionofanovelimmuneresponsepredictionsignaturetopredicttheefficacyofimmunecheckpointinhibitorsinclearcellrenalcellcarcinomapatientsheliyon96may252023
AT geyang corrigendumtoconstructionofanovelimmuneresponsepredictionsignaturetopredicttheefficacyofimmunecheckpointinhibitorsinclearcellrenalcellcarcinomapatientsheliyon96may252023
AT liujian corrigendumtoconstructionofanovelimmuneresponsepredictionsignaturetopredicttheefficacyofimmunecheckpointinhibitorsinclearcellrenalcellcarcinomapatientsheliyon96may252023
AT anguangyu corrigendumtoconstructionofanovelimmuneresponsepredictionsignaturetopredicttheefficacyofimmunecheckpointinhibitorsinclearcellrenalcellcarcinomapatientsheliyon96may252023

Ejemplares similares